DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck’s epilepsy research efforts are featured in a new report on neurological disorders from the Pharmaceutical Research and Manufacturers of America (PhRMA). The report is accompanied by an educational video about the science of epilepsy, including the role of neuroinflammation and how a better understanding of the neuroinflammatory processes may yield new seizure therapies. The video can be viewed here.
“Almost every neurological disease that has been studied has been shown to have some component of neuroinflammation”
The video features three scientists from Lundbeck’s US research organization. Lundbeck researchers in the U.S. focus entirely on brain disorders, exploring the role of neuroinflammation in conditions including Alzheimer’s disease, depression, Parkinson’s disease, schizophrenia, epilepsy and others.
“Almost every neurological disease that has been studied has been shown to have some component of neuroinflammation,” said Stevin Zorn, PhD, executive vice president of Lundbeck Research USA. “By studying neuroinflammation biologies, we’re hoping to identify new ways to treat complicated neurological disorders like epilepsy and related seizure disorders. While this research has a ways to go before reaching the bedside, it has the potential to play an important role in the future treatment of epilepsy.”
Partnering to Make a Difference in Epilepsy
In addition to its own R&D efforts, Lundbeck supports the scientific and professional epilepsy community to accelerate research and education. Since 2011, Lundbeck has supported more than 120 continuing medical education initiatives – including multiple J. Kiffin Penry programs – and has provided ongoing support for numerous investigator-initiated clinical trials. In addition, to help seed tomorrow’s leading brain researchers, Lundbeck partners with academic institutions that focus on brain-related research. For instance, Lundbeck hosts student interns from several universities such as Drew University, Madison, NJ, one of the few liberal arts colleges with an undergraduate neuroscience program, and has donated high tech equipment including a nuclear magnetic resonance (NMR) spectrometer to the school to advance its students’ education to enable hands-on learning with cutting edge equipment.
At the core of Lundbeck’s work is support and partnership in the patient community. For instance, Studio E: The Epilepsy Art Therapy Program is made possible through a partnership between Lundbeck, the Epilepsy Foundation and more than 30 of its local affiliates nationwide. Lundbeck also partners with the Lennox-Gastaut Syndrome Foundation to fund a scholarship allowing many families to attend the organization’s annual Family & Professional Conference, and supports all of the Tuberous Sclerosis Alliance’s local walks and educational programs. Our employees are inspired by actively participating in hundreds of epilepsy events each year.
“Seeing the person behind the disease is at the core of everything we do at Lundbeck – from early-stage research and drug development to our interactions with professionals, patients and their families,” said Daniel Brennan, vice president and general manager of the neurology business at Lundbeck. “This is why we are so active not only in partnering with professionals, but also advocacy groups, people with challenging seizure disorders and their caregivers. This engagement is what educates and motivates us to do our best work every day.”
Learn more about Lundbeck’s epilepsy support and programs at YourPartnerInEpilepsy.com.
About Lundbeck in the U.S.
A wholly owned subsidiary of H. Lundbeck A/S in Denmark, Lundbeck U.S. is headquartered in Deerfield, Illinois, and is committed to providing innovative specialty therapies that fulfill unmet medical needs of people with brain disorders. In its research late-stage research pipeline, the company has neurology compounds under investigation for Alzheimer’s disease, stroke and epilepsy, in addition to therapies in development for mental health disorders.
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain diseases. For this purpose, Lundbeck is engaged in the entire value chain throughout research, development, production, marketing and sales of pharmaceuticals across the world. The company’s products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy, Huntington’s, Alzheimer’s and Parkinson’s diseases. Lundbeck’s pipeline consists of several mid- to late-stage development programs.
Lundbeck employs more than 5,800 people worldwide, 2,000 of whom are based in Denmark. We have employees in 57 countries and our products are registered in more than 100 countries. We have research centers in Denmark, China and the United States and production facilities in Italy, France, Mexico, China and Denmark. Lundbeck generated revenue of approximately DKK 15 billion in 2012. Lundbeck’s shares are listed on the stock exchange in Copenhagen under the symbol ”LUN.” Lundbeck has a sponsored Level 1 ADR programme listed in the US (OTC) under the symbol ”HLUYY.” For additional information, we encourage you to visit our corporate site www.lundbeck.com.